The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
Clinical trial NCT04356872 · UNKNOWN
Trial details
- NCT number
- NCT04356872
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-08
- Primary completion
- 2022-03-30
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.